UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Nature communications, 2022-06, Vol.13 (1), p.3246-11, Article 3246

2022

Volltextzugriff (PDF)

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Nature communications, 2023-01, Vol.14 (1), p.260-260, Article 260

2023

Volltextzugriff (PDF)

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

European journal of cancer (1990), 2018-11, Vol.103, p.17-23

2018

Volltextzugriff (PDF)

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Annals of oncology, 2024-08, Vol.35 (8), p.707-717

2024

Volltextzugriff (PDF)

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-01, Vol.28 (1), p.1-3

2016

Volltextzugriff (PDF)

Post-operative endophthalmitis: the application of hazard analysis critical control points (HACCP) to an infection control problem

The Journal of hospital infection, 2001-09, Vol.49 (1), p.14-22

2001

Volltextzugriff (PDF)

An early review of 800 laparoscopic cholecystectomies at a university-affiliated community teaching hospital

The American surgeon, 1992-03, Vol.58 (3), p.206

1992

Volltextzugriff (PDF)

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials

European journal of gynaecological oncology, 2012, Vol.33 (2), p.211-213

2012

Volltextzugriff (PDF)

A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens

Journal of antimicrobial chemotherapy, 1994-11, Vol.34 (5), p.639-648

1994

Volltextzugriff (PDF)

An institutional review of the management of choledocholithiasis in 1616 patients undergoing laparoscopic cholecystectomy

The American surgeon, 1994-04, Vol.60 (4), p.273

1994

Volltextzugriff (PDF)

Handbook of culture media for food and water microbiology

3rd ed., 2012

Volltextzugriff (PDF)

Hereditary and Sporadic Cancers Respond to Niraparib

Cancer discovery, 2013-08, Vol.3 (8), p.OF8-OF8

2013

Volltextzugriff (PDF)

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors

JOURNAL OF CLINICAL ONCOLOGY, 2019, Vol.37 (15_suppl), p.TPS3151-TPS3151

2019

Volltextzugriff (PDF)

Abstract OT1-01-07: PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-01-07-OT1-01-07

2019

Volltextzugriff (PDF)

Carotid patch angioplasty: Immediate and long-term results

Journal of vascular surgery, 1990-09, Vol.12 (3), p.326-333

1990

Volltextzugriff (PDF)

Carbon cycling in northern peatlands

1, 2009

Volltextzugriff (PDF)

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2519-2519

2010

Volltextzugriff (PDF)

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-14-26

2016

Volltextzugriff (PDF)

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2613-2613

2010

Volltextzugriff (PDF)

Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-04-01-OT1-04-01

2017

Volltextzugriff (PDF)

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-11-OT2-01-11

2017

Volltextzugriff (PDF)

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2555-2555

2011

Volltextzugriff (PDF)

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3024-3024

2011

Volltextzugriff (PDF)

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3004-3004

2011

Volltextzugriff (PDF)

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3001-3001

2011

Volltextzugriff (PDF)

1 – 25 von 2.659

Suche als RSS-Feed

Aktive Filter

PublikationsformReviews

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.334)
Mit Volltextzugriff
(2.076)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.729)
Life Sciences & Biomedicine
(1.389)
Humans
(950)
Female
(733)
Biological And Medical Sciences
(589)
Male
(476)
Medical Sciences
(402)
Animals
(400)
Adult
(378)
Physical Sciences
(277)
Middle Aged
(272)
Fundamental And Applied Biological Sciences. Psychology
(202)
Aged
(196)
Pregnancy
(180)
Physics
(152)
Infectious Diseases
(147)
Surgery
(140)
Technology
(135)
Adolescent
(121)
Child
(115)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications

Post-operative endophthalmitis: the application of hazard analysis critical control points (HACCP) to an infection control problem

An early review of 800 laparoscopic cholecystectomies at a university-affiliated community teaching hospital

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials

A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens

An institutional review of the management of choledocholithiasis in 1616 patients undergoing laparoscopic cholecystectomy

Handbook of culture media for food and water microbiology

Hereditary and Sporadic Cancers Respond to Niraparib

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors

Abstract OT1-01-07: PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer

Carotid patch angioplasty: Immediate and long-term results

Carbon cycling in northern peatlands

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941

Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers

Aktive Filter

Suchergebnisse filtern